Nicox Receives €3M Milestone as Kowa Submits NCX 470 NDA to FDA
Kowa submits NCX 470 NDA to FDA for the dual-mechanism glaucoma treatment. Nicox collects €3M milestone as partner handles...
No videos found.
Eurobio Scientific Completes €145M CareDx Transplant Division Acquisition
Eurobio Scientific completes €145M CareDx Transplant Division Acquisition to expand HLA typing and post-transplant monitoring capabilities across Europe and...
Evotec Launches J.TRAIN Modular Biologics Manufacturing Platform
Evotec launches J.TRAIN modular biologics manufacturing platform, claiming 500+ kg drug output in under 10,000 sq ft with 18-month...
Xellar Biosystems Raises $50M Series A for Drug Discovery Data Platform
Xellar Biosystems raises $50M Series A to build a drug discovery data platform integrating organ-on-chip systems and AI for...
Calidi Biotherapeutics Appoints Corsee Sanders to Board
Calidi Biotherapeutics appoints Corsee Sanders, clinical operations veteran from Genentech and Juno, to board ahead of CLD-401 IND filing.
Mark DeLong Appointed CEO of Arrakis Therapeutics for DM1 Program
Mark DeLong appointed CEO of Arrakis Therapeutics to advance an oral small molecule treatment for myotonic dystrophy type 1...
Ollin Biosciences Raises $330M Series B for OLN324 Retinal Disease Program
Ollin Biosciences raises $330M Series B for OLN324 retinal disease program with Phase 3 trials launching in 2026 for...
$330M Oversubscribed: Ollin’s Faricimab Challenger Just Became the Most Funded Retinal Disease Bet of 2026
Ollin Biosciences closed an oversubscribed $330M Series B on June 24 to run global Phase 3 trials of OLN324...
Coherus, Zumutor Begin Phase 1 Trial of LOQTORZI With NK Cell Therapy ZM008
Coherus and Zumutor launch Phase 1 trial of LOQTORZI with NK cell therapy ZM008 across five cancer types to...
Boundless Bio to Merge With Serapha Bio in $230M Gene Therapy Deal
Boundless Bio merges with Serapha Bio in $230M gene therapy deal to advance SERP-01, an in vivo base editing...